Related references
Note: Only part of the references are listed.Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
Jose Fernandez-Velasco et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Advances in the Treatment of Multiple Sclerosis
Carolyn Goldschmidt et al.
NEUROLOGIC CLINICS (2021)
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
N. R. Oksbjerg et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
Enric Monreal et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
IgA and the intestinal microbiota: the importance of being specific
Oliver Pabst et al.
MUCOSAL IMMUNOLOGY (2020)
Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis
Anne-Katrin Probstel et al.
SCIENCE IMMUNOLOGY (2020)
The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies
Rui Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10 (vol 176, pg 610, 2019)
Olga L. Rojas et al.
CELL (2019)
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Simon Faissner et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients
Silvia Medina et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
B-Cell Therapy for Multiple Sclerosis: Entering an Era
Ariele L. Greenfield et al.
ANNALS OF NEUROLOGY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis
Laura E. Baldassari et al.
DRUGS (2018)
Multiple sclerosis
Massimo Filippi et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Natural antibodies - facts known and unknown
Joanna Palma et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shabnam Shalapour et al.
NATURE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Features of Human CD3+CD20+ T Cells
Elisabeth Schuh et al.
JOURNAL OF IMMUNOLOGY (2016)
Natural IgM: Beneficial Autoantibodies for the Control of Inflammatory and Autoimmune Disease
Caroline Groenwall et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Primary-progressive multiple sclerosis (vol 6, pg 903, 2007)
D. Miller et al.
LANCET NEUROLOGY (2009)
Primary-progressive multiple sclerosis
David H. Miller et al.
LANCET NEUROLOGY (2007)
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
S Cepok et al.
BRAIN (2005)
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis
NL Monson et al.
ARCHIVES OF NEUROLOGY (2005)
Share Paper
